

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

LNCaP C4-2

RRID:CVCL_4782

Type: Cell Line

Proper Citation

RRID:CVCL_4782

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4782

Proper Citation: RRID:CVCL_4782

Description: Cell line LNCaP C4-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:8169003](#), [PMID:15162376](#), [PMID:26499105](#), [PMID:29194687](#), [PMID:35502546](#)

Comments: Characteristics: Exhibits androgen-independent growth associated with skeletal metastasis, produces metastases when injected either subcutaneously or orthotopically in intact or castrated mice., Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP C4-2

Synonyms: LNCaP-C4-2, LNCaP subline C4-2, C4-2, C42, Sp 2817

Cross References: BTO:BTO_0005672, ATCC:CRL-3314, cancercellines:CVCL_4782, ChEMBL-Cells:ChEMBL4295439, ChEMBL-Targets:ChEMBL4296460, CLS:305752, Cosmic:1330914, GEO:GSM3145590, GEO:GSM3145694, PubChem_Cell_line:CVCL_4782, Wikidata:Q54902814

ID: CVCL_4782

Hierarchy: cvcl_4783

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260905T181035+0000

Ratings and Alerts

No rating or validation information has been found for LNCaP C4-2.

No alerts have been found for LNCaP C4-2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 390 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gordon N, et al. (2026) PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. *Molecular oncology*, 20(6), 1626.

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. *Cellular signalling*, 141, 112368.

Kim SH, et al. (2026) Synthesis of Bispecific Conjugates by ADP-Ribosyl Cyclases. *Advanced science (Weinheim, Baden-Wurtemberg, Germany)*, 13(13), e18329.

Zheng W, et al. (2026) hsa-circKLK3-25 promotes epithelial-mesenchymal transition and malignant progression of prostate cancer through the JNK/ERK signaling pathway. *American journal of cancer research*, 16(3), 1081.

Rodrigues SD, et al. (2026) Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression. *bioRxiv : the preprint server for biology*.

Huang J, et al. (2026) The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth. *Cancer gene therapy*.

Zhao D, et al. (2026) Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. *Science advances*, 12(3), eady5324.

Liu S, et al. (2026) Betulinic acid induces lysosome-dependent death in prostate cancer by targeting DDX5. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 155, 158143.

Fang B, et al. (2026) EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. *The*

Journal of clinical investigation, 136(11).

Luo T, et al. (2026) Butyrylated PGAM5-Triggered and GSH-Responsive Cysteine Polymer Nanoparticles for CBL0137 Delivery to Enhance Necroptosis in Prostate Cancer. *Advanced healthcare materials*, e71387.

Chen Y, et al. (2025) ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. *iScience*, 28(10), 113520.

Sheng H, et al. (2025) KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer. *Oncogene*.

Hofstad M, et al. (2025) Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. *Oncogene*, 44(22), 1746.

Guo C, et al. (2025) ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling. *Cell biology and toxicology*, 41(1), 107.

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. *Cell reports. Medicine*, 6(1), 101890.

Huang Y, et al. (2025) Development and validation of a kinase-related gene signature as a novel diagnostic and prognostic model for prostate cancer. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(4), 167722.

Hirani R, et al. (2025) BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. *Cell reports*, 44(6), 115779.

Baker MJ, et al. (2025) VAV2 Drives EGFR-Mediated Rac1 Responses in Prostate Cancer. *Molecular cancer research : MCR*, 23(8), 684.

Labaf M, et al. (2025) Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells. *Molecular cancer therapeutics*, 24(5), 772.

Ye Q, et al. (2025) A Peptide-Based PROTAC Degradar of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition. *Cancer research*, 85(18), 3490.